Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Rating of “Moderate Buy” by Brokerages

Posted by Geri Gentry on May 27th, 2026

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Free Report) have received an average recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $46.50.

A number of analysts have recently weighed in on TYRA shares. William Blair started coverage on Tyra Biosciences in a research report on Tuesday, February 10th. They set an “outperform” rating on the stock. Guggenheim started coverage on Tyra Biosciences in a research report on Tuesday, April 14th. They set a “buy” rating and a $54.00 price objective on the stock. Canaccord Genuity Group initiated coverage on Tyra Biosciences in a research report on Monday, April 6th. They set a “buy” rating and a $50.00 price objective on the stock. Wedbush increased their target price on Tyra Biosciences from $37.00 to $53.00 and gave the company an “outperform” rating in a report on Friday, February 13th. Finally, Jefferies Financial Group increased their target price on Tyra Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a report on Tuesday, February 3rd.

Check Out Our Latest Analysis on Tyra Biosciences

Tyra Biosciences Trading Up 3.4%

Tyra Biosciences stock opened at $33.59 on Friday. Tyra Biosciences has a twelve month low of $8.75 and a twelve month high of $40.65. The stock’s fifty day simple moving average is $35.92 and its 200-day simple moving average is $29.98. The firm has a market capitalization of $2.00 billion, a P/E ratio of -15.41 and a beta of 0.79.

Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.04). Sell-side analysts predict that Tyra Biosciences will post -2.69 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Gilla Kaplan sold 14,295 shares of the stock in a transaction on Wednesday, March 25th. The stock was sold at an average price of $36.97, for a total value of $528,486.15. Following the transaction, the director owned 28,231 shares of the company’s stock, valued at $1,043,700.07. This represents a 33.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 12.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Tyra Biosciences

Several large investors have recently bought and sold shares of TYRA. Commodore Capital LP increased its holdings in Tyra Biosciences by 226.3% in the second quarter. Commodore Capital LP now owns 3,100,000 shares of the company’s stock valued at $29,667,000 after buying an additional 2,150,000 shares during the last quarter. Janus Henderson Group PLC increased its holdings in Tyra Biosciences by 32.5% in the first quarter. Janus Henderson Group PLC now owns 3,890,589 shares of the company’s stock valued at $148,867,000 after buying an additional 955,147 shares during the last quarter. Farallon Capital Management LLC increased its holdings in Tyra Biosciences by 80.7% in the fourth quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company’s stock valued at $54,337,000 after buying an additional 923,000 shares during the last quarter. Jennison Associates LLC purchased a new position in Tyra Biosciences in the first quarter valued at $24,222,000. Finally, Caligan Partners LP increased its holdings in Tyra Biosciences by 266.8% in the third quarter. Caligan Partners LP now owns 696,825 shares of the company’s stock valued at $9,749,000 after buying an additional 506,875 shares during the last quarter. Hedge funds and other institutional investors own 84.14% of the company’s stock.

About Tyra Biosciences

(Get Free Report)

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.